Fia Cialdella

Fia Cialdella

Auto-generated profile, based on publicly available information

Fia Cialdella

Affiliations Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands, Department of Neurology & Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in Radiotherapy and Oncology
Verified
Journal Article
Open access
PDF file
SHSelena I. Huisman
Selena I. Huisman
ABArthur T.J. van der Boog
Arthur T.J. van der Boog
FCFia Cialdella
Fia Cialdella
JVJoost J.C. Verhoeff
Joost J.C. Verhoeff
SDSzabolcs David
Szabolcs David
• Brain morphology changes after radiotherapy can be described as accelerated aging. • Up to 3 times accelerated brain aging rate. • Anatomically well-defined areas for brain age prediction.

29 March 2024 in Neuro-Oncology Practice
Verified
Journal Article
Open access
PDF file
EGEva Elisabeth van Grinsven
Eva Elisabeth van Grinsven
FCFia Cialdella
Fia Cialdella
YMYoniet Gmelich Meijling
Yoniet Gmelich Meijling
JVJoost J C Verhoeff
Joost J C Verhoeff
MPMarielle Philippens
Marielle Philippens
MZMartine van Zandvoort
Martine van Zandvoort
The increasing incidence of brain metastases (BMs) and improved survival rates underscore the necessity to investigate the effects of treatments on individuals. The aim of this study was to evaluate the individual trajectories of subjective and objective cognitive performance after radiotherapy in patients with BMs. The study population consisted of adult patients with BMs referred for radiotherapy. A semi-structured interview and comprehensive neurocognitive assessment (NCA) were used to assess both subjective and objective cognitive performance before, 3 months and ≥ 11 months after radiotherapy. Reliable change indices were used to identify individual, clinically meaningful changes. Thirty-six patients completed the 3-month follow-up, and 14 patients completed the ≥ 11-months follow-up. Depending on the domain, subjective cognitive decline was reported by 11–22% of patients. In total, 50% of patients reported subjective decline in at least one cognitive domain. Intracranial progression 3 months postradiotherapy was a risk-factor for self-reported deterioration (P = .031). Objective changes were observed across all domains, with a particular vulnerability for decline in memory at 3 months postradiotherapy. The majority of patients (81%) experienced both a deterioration as well as improvement (eg, mixed response) in objective cognitive functioning. Results were similar for the long-term follow-up (3 to ≥11 months). No risk factors for objective cognitive change 3 months postradiotherapy were identified. Our study revealed that the majority of patients with BMs will show a mixed cognitive response following radiotherapy, reflecting the complex impact. This underscores the importance of patient-tailored NCAs 3 months postradiotherapy to guide optimal rehabilitation strategies.

27 January 2026 in Technical Innovations & Patient Support in Radiation Oncology
Verified
Journal Article
Open access
FCFia Cialdella
Fia Cialdella
DBDanique E. Bruil
Danique E. Bruil
ABArthur T.J. van der Boog
Arthur T.J. van der Boog
SNSteven H.J Nagtegaal
Steven H.J Nagtegaal
FVFilip Y.F.L. de Vos
Filip Y.F.L. de Vos
SDSzabolcs David
Szabolcs David
Non-small cell lung cancer (NSCLC), the most common type of lung cancer frequently leads to brain metastases (BMs), which are associated with a poor prognosis. Radiotherapy is the main treatment for BMs, but irradiates healthy tissue, including neural stem cells (NSCs). NSCs reside in neurogenic niches, mainly the subventricular zone (SVZ) and the subgranular zone (SGZ) within the hippocampus (HPC), which support neurogenesis and brain repair. Radiation damage to NSCs may influence overall survival (OS). Our study aims to evaluate the impact of any radiotherapy dose on NSCs on OS in patients with BMs from NSCLC, with lesion contact explored as a secondary aim. We retrospectively included 138 NSCLC patients with BMs and delineated NSC regions on T1 MR-images. Kaplan-Meier (KM) analysis and Cox regression assessed associations between OS, mean radiotherapy dose to SVZ and HPC, and lesion contact. Higher radiotherapy dose on the SVZ and HPC were significantly associated with reduced OS, with a hazard ratio (HR) of 1.306 ([95% CI 1.043–1.635], p = 0.019) and 1.222 ([95% CI 1.008–1.483], p = 0.041), respectively. Lesion contact with neurogenic niches was also independently significant (SVZ: HR 1.968 [95% CI 1.094–3.542], p = 0.023 and HPC: HR 5.751 [95% CI 1.733–19.07], p = 0.004), although lesion contact was uncommon. Unintended radiotherapy dose to neurogenic niches is independently associated with worse OS in NSCLC patients with brain metastases, and tumor contact with these regions also shows an adverse association. These findings support considering the SVZ and hippocampus as organs–at–risk in SRS planning and motivate prospective validation in larger, controlled cohorts.

9 February 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AJA. M. de Jong
A. M. de Jong
ABA. T. J. van der Boog
A. T. J. van der Boog
CPC. C. B. Post
C. C. B. Post
FCF. Cialdella
F. Cialdella
DED. B. P. Eekers
D. B. P. Eekers
JVJ. J. C. Verhoeff
J. J. C. Verhoeff
Background: Reirradiation is a widely accepted option for second-line treatment in patients with recurrent glioma. However, no standard radiation regimen has been defined. Hypofractionation is aimed at reducing patients’ burden while maintaining the survival benefit, but may increase the risk of radionecrosis. The primary objective of this study is to determine if reirradiation in just 4 fractions is non-inferior to 10 fractions, regarding survival after reirradiation. Methods: RISING trial A was an open label, randomized, non-inferiority, phase III trial with 1:1 allocation for 130 patients among all participating centers but failed to recruit according to planning. RISING trial B will be a phase II, multi-center, clinical trial with a historic control group. The experimental group receives 4 stereotactic fractions. The historic control group has received 10 fractions (standard-of-care) with a biologically equivalent dose on surrounding brain tissue. The primary endpoint is overall survival after reirradiation. The key secondary endpoint is progression-free survival. Other secondary endpoints are recurrence patterns, toxicity (specifically clinically relevant radionecrosis) and anti-edema treatment. We will collect and report on Health-Related Quality of Life (HRQoL) data in the experimental arm. Discussion: We expect to demonstrate the non-inferiority and safety of a 4-fraction hypofractionation schedule for reirradiation of gliomas. This schedule may then become a standard-of-care option with minimal burden for patients with recurrent glioma, and limited use of scarce healthcare resources. Trial registration: Registered at Netherlands Trial Register (NTR), Trial ID: NL72766.041.20, registered at 07-04-2020, https://www.onderzoekmetmensen.nl/en/trial/52643

7 October 2025 in Neuro-Oncology Practice
Verified
Journal Article
Open access
FCFia Cialdella
Fia Cialdella
EGEva E van Grinsven
Eva E van Grinsven
SNSteven H J Nagtegaal
Steven H J Nagtegaal
ABArthur T J van der Boog
Arthur T J van der Boog
CHCeleste C Hinkert
Celeste C Hinkert
JVJoost J C Verhoeff
Joost J C Verhoeff
BackgroundBrain metastases (BMs) affect >30% of patients with cancer. Beyond survival, quality of life (QoL), and disease progression are critical concerns for both patients and their caregivers. We present the design of COIMBRA (Cohort for patient-reported Outcomes, Imaging, and trial inclusion in Metastatic BRAin disease), clinical characteristics, and pre-radiotherapy QoL data for patients and caregivers. Methods: COIMBRA is an observational, prospective, single-center cohort at UMC Utrecht, the Netherlands, focusing on BMs patients planned for (fractionated) stereotactic radiosurgery (SRS) and their caregivers. We collected clinical characteristics, imaging, and QoL (patient and caregiver) data via patient-reported outcome (PRO) questionnaires. PROs include the EORTC QLQ-C30, BN20, EQ-5D-3L (including VAS), CFQ, HADS, MFI, and CSI. PROs were compared with reference values from the literature for healthy, cancer, and brain tumor populations. Results: From April 2019 to April 2023, 377 patients (50.4% male, median age 66 years) who received stereotactic radiosurgery, were included. Two hundred and seventy-six patients and 115 caregivers consented to PROs. Patients reported lower QoL compared to healthy individuals and primary brain tumor patients, with worse role- and cognitive functioning compared to patients with cancer. Pre-radiotherapy, 1/3 of the caregivers felt overwhelmed. Almost 40% of them report signs of anxiety, which is less than caregivers of cancer or primary brain tumor patients. Conclusions: These data from a large cohort of patients with BMs and their caregivers underscore the unique clinical profile of this vulnerable population. These findings highlight the urgent need for targeted support systems to address unmet needs of both patients and caregivers.

1 August 2023 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
FCFia Cialdella
Fia Cialdella
EGEva van Grinsven
Eva van Grinsven
ABArthur van der Boog
Arthur van der Boog
SNSteven Nagtegaal
Steven Nagtegaal
ESErn Smid
Ern Smid
JVJoost Verhoeff
Joost Verhoeff
INTRODUCTION: Brain metastases (BMs) occur in 10-30% of adult patients with cancer. The therapeutic approach for BMs depends on several factors including lesion number, location and size, primary cancer type, and the patient’s overall health. ASCO-SNO-ASTRO guidelines conditionally recommend stereotactic radiosurgery (SRS) for 1-10 BMs. The aim of this study was to investigate the outcomes of radiotherapy in patients with 5 or more BMs using SRS. METHODS: We implemented the prospective Cohort for patient-reported Outcomes, Imaging and trial inclusion in Metastatic BRAin disease (COIMBRA) to examine all patients with BM(s) who underwent radiotherapy. In this sub-study we investigated overall survival (OS) and health related quality of life (HRQoL) for 47 patients with 5 to 20 BMs. We evaluated patients’ HRQoL using the EQ5D-VAS, at baseline and at 3 monthly intervals after radiotherapy. RESULTS: Median OS was 21.3 months for patients with 5-10 BMs (n=38) and 12.5 months for patients with >10 BMs (n=9). Questionnaires at both baseline and 6 months after radiotherapy showed stability or improvement on the EQ5D-VAS after radiotherapy in 58.1%. Additionally, independence in self-care was not limited before or after SRS. Also, the proportion of patients (66.7%) reporting no limitation on their ability to do daily activities remained stable after radiotherapy. Fewer patients reported pain or other discomfort after SRS compared to before (25% vs 40%). CONCLUSION: Our findings suggest that radiotherapy may improve QoL in patients with 5-20 BMs. Furthermore, compared to the literature, we observed a prolonged OS in this prospective cohort, suggesting that SRS should be considered as the treatment option for these patients. These results highlight the need for further investigation of the role of SRS instead of Whole Brain Radiotherapy (WBRT) in the management of patients with multiple BMs.